Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

14 Jul 2026, 01:20 UTC · 2h ago

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

Which stocks this story touches

How each ticker is affected

LCTX+0.30
The company is providing updates and discussing its manufacturing strategy for its COR1 cell transplant program.

Read original · https://seekingalpha.com/article/4921707-lineage-cell-therapeutics-inc-lctx-discusses-cor1-cell-transplant-program-and-manufacturing

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

$LCTX#biotech#cell_therapy#cornea#manufacturing

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

Sector Rotation+0.200

6 related stories

Proactive Investors
11h ago
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
- biotech
- ophthalmology
Read

Lineage Cell Therapeutics… — LCTX +0.30 | NewsImpactScreener

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

How each ticker is affected

Track these names every morning.

Impact by category

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

How each ticker is affected

Track these names every morning.

Impact by category

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

Biggest drivers

Most positively impacted

Most negatively impacted

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

SILITH and UMC Achieve Mass Production Milestone for Silicon Photonics

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

SANMINA CORPORATION INVITES YOU TO JOIN ITS THIRD QUARTER FISCAL 2026 EARNINGS CONFERENCE CALL

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript

How each ticker is affected

Track these names every morning.

Impact by category

Next reads from the same story arc

ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant

Biggest drivers

Most positively impacted

Most negatively impacted

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

SILITH and UMC Achieve Mass Production Milestone for Silicon Photonics

Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights

SANMINA CORPORATION INVITES YOU TO JOIN ITS THIRD QUARTER FISCAL 2026 EARNINGS CONFERENCE CALL

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease